Antiviral Activity/Safety of a Second-Generation HIV-1 Maturation Inhibitor
Background: BMS-955176 is a 2nd-generation HIV-1 maturation inhibitor (MI). A 1st”‘generation MI (bevirimat) showed clinical efficacy in early-phase studies, but ~50% of subjects had reduced viral susceptibility associated with naturally occurring polymorphisms in Gag. We assessed BMS-955176 antiviral activity, safety, and exposure–response during 10 days of monotherapy in HIV-1, subtype B-infected subjects. Methods: AI468002 (NCT01803074)…